Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left">LONDON and BOSTON and BUDAPEST, Hungary, July 02, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies based on its proprietary PEPI...
Overview
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left">LONDON and BOSTON and BUDAPEST, Hungary, July 02, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies based on its proprietary PEPI...
Source
Originally published at markets.businessinsider.com.
